Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2
  1. Home
  2. Publications
  3. Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2

Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2

Authors:
  • FAF. Javier Ampudia-Blasco
    F. Javier Ampudia-Blasco

Publisher website
Google Scholar
  • 1 September 2013
    • journal article
    • review article
    • Published by Elsevier in Medicina Clinica
    • Vol. 141, 36-43
    • DOI:10.1016/s0025-7753(13)70062-9
    • PMID:24444523
Abstract
No abstract available
Keywords
  • CLINICAL TRIALS
  • COTRANSPORTADORES DE SODIO-GLUCOSA
  • DAPAGLIFLOZIN
  • DAPAGLIFLOZINA
  • DIABETES TIPO 2
  • EFFICACY
  • EFICACIA
  • ESTUDIOS CLÍNICOS
  • GLUCOSÚRICOS
  • INHIBIDORES DE SGLT2
  • SGLT2 INHIBITORS
  • SAFETY
  • SEGURIDAD
  • SODIUM-GLUCOSE CO-TRANSPORTERS
  • TOLERABILITY
  • TOLERANCIA
  • TYPE 2 DIABETES
Cited by 28 articles
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.